No Data
INNOCARE's BCL2 inhibitors are expected to be included in breakthrough therapeutic varieties.
InnoCare Pharma to Review Q1 2025 Financial Results
INNOCARE (09969.HK) will hold a Board of Directors meeting on May 13 to approve the first quarter performance.
Glory Exchange, on April 28, announced that INNOCARE (09969.HK) will hold a Board of Directors meeting on May 13, 2025, to consider and approve the unaudited first quarter results of the company and its subsidiaries for the three months ending March 31, 2025, and its release.
INNOCARE: DATE OF BOARD MEETING
INNOCARE: Annual Report 2024
Zhuhai International: The pharmaceutical industry in China is expected to continue the valuation recovery this year, with the market for Innovative Drugs likely to differentiate.
Zhao Yin International published a report indicating that, driven by positive factors such as the export Trade of Innovative Drugs, optimization of domestic procurement policies, the implementation of the Class B medical insurance catalog for Innovative Drugs, the revival of tenders for Medical Devices, and the recovery of domestic demand, the Pharmaceutical Industry is expected to continue experiencing valuation repair in 2025.
